Syngoi Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Syngoi Technologies is a private, pre-revenue biotech firm positioning itself as a specialized manufacturer of synthetic linear DNA for advanced therapies. The company's core innovation is a proprietary, enzymatic, cGMP-compliant production process designed to be more efficient and scalable than traditional methods. By focusing on providing high-quality, project-specific DNA constructs, Syngoi aims to serve as a critical supplier to cell and gene therapy developers, addressing a key bottleneck in the field. The company is in an early stage, building its technological platform and commercial relationships from its base in Spain's growing biotech hub.

Genetics & Genomics

Technology Platform

Proprietary, cell-free enzymatic process for the cGMP manufacturing of optimized linear synthetic DNA, utilizing a library of adaptors for customization.

Opportunities

The rapid growth of the cell and gene therapy market creates immense demand for high-quality, scalable DNA starting materials.

Syngoi's enzymatic production method offers potential speed, purity, and cost advantages over traditional plasmid DNA fermentation, positioning it to capture share in a critical supply chain bottleneck.

Tailoring DNA constructs for specific client projects allows for premium, value-added services.

Risk Factors

The company must prove its novel enzymatic platform at commercial scale and achieve cost-competitiveness with established methods.

Market adoption is risky as biopharma clients are often reluctant to change critical raw material suppliers.

Syngoi faces significant competition from other synthetic DNA startups and large CDMOs investing in next-generation DNA production.

Competitive Landscape

Syngoi competes with traditional contract development and manufacturing organizations (CDMOs) producing plasmid DNA via fermentation (e.g., Thermo Fisher, Charles River, Aldevron) and a growing cohort of startups developing enzymatic DNA synthesis technologies (e.g., DNA Script, Ansa Biotechnologies, Touchlight Genetics). Its differentiation lies in a specific focus on linear, cGMP-grade DNA for advanced therapies rather than general oligo synthesis.

More companies in Synthetic Biology →More companies in Spain →